{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:20:36Z","timestamp":1793733636593,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2019J01457"],"award-info":[{"award-number":["2019J01457"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00262-020-02803-5","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T06:04:00Z","timestamp":1613109840000},"page":"2559-2576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors"],"prefix":"10.1007","volume":"70","author":[{"given":"Li","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-5887","authenticated-orcid":false,"given":"Xianhe","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"4","key":"2803_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"26","key":"2803_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"19","key":"2803_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"11","key":"2803_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"issue":"19","key":"2803_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"19","key":"2803_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung Cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"6349","key":"2803_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"issue":"9","key":"2803_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182\u20131191. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9","journal-title":"Lancet Oncol"},{"issue":"10088","key":"2803_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzio TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"issue":"5","key":"2803_CR10","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013","journal-title":"JAMA Oncol"},{"key":"2803_CR11","doi-asserted-by":"publisher","first-page":"605478","DOI":"10.1155\/2015\/605478","volume":"2015","author":"A Ito","year":"2015","unstructured":"Ito A, Kondo S, Tada K, Kitano S (2015) Clinical development of immune checkpoint inhibitors. Biomed Res Int 2015:605478. https:\/\/doi.org\/10.1155\/2015\/605478","journal-title":"Biomed Res Int"},{"issue":"4","key":"2803_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.21037\/tlcr.2019.08.09","volume":"8","author":"YY Xu","year":"2019","unstructured":"Xu YY, Wan B, Chen X, Zhan P, Zhao Y, Zhang T et al (2019) The association of PD-L1 expression with the efficacy of anti-PD-1\/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res 8(4):413\u2013428","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"2803_CR13","doi-asserted-by":"publisher","first-page":"e1629258","DOI":"10.1080\/2162402X.2019.1629258","volume":"8","author":"DD Cao","year":"2019","unstructured":"Cao DD, Xu HL, Xu XM, Guo T, Ge W (2019) High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Onconimmunology 8(9):e1629258. https:\/\/doi.org\/10.1080\/2162402X.2019.1629258","journal-title":"Onconimmunology"},{"issue":"4","key":"2803_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2803_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"issue":"1","key":"2803_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2803_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol 44(2):117\u2013122. https:\/\/doi.org\/10.1111\/1346-8138.13520","journal-title":"J Dermatol"},{"issue":"10","key":"2803_CR18","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/1759-7714.13187","volume":"10","author":"M Tone","year":"2019","unstructured":"Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T et al (2019) High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer 10(10):2006\u20132012. https:\/\/doi.org\/10.1111\/1759-7714.13187","journal-title":"Thorac Cancer"},{"issue":"12","key":"2803_CR19","doi-asserted-by":"publisher","first-page":"e83138","DOI":"10.1371\/journal.pone.0083138","volume":"8","author":"N Panic","year":"2013","unstructured":"Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S (2013) Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS ONE 8(12):e83138. https:\/\/doi.org\/10.1371\/journal.pone.0083138","journal-title":"PLoS ONE"},{"issue":"15","key":"2803_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012","journal-title":"JAMA"},{"key":"2803_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"2803_CR22","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"2803_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1479-5876-12-116","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M et al (2014) Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116. https:\/\/doi.org\/10.1186\/1479-5876-12-116","journal-title":"J Transl Med"},{"issue":"4","key":"2803_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","volume":"20","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M et al (2019) Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer 20(4):237\u2013247. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.006","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"2803_CR25","doi-asserted-by":"publisher","first-page":"S645","DOI":"10.1200\/JCO.2019.37.7_suppl.645","volume":"37","author":"R Elias","year":"2019","unstructured":"Elias R, Yan F, Singla N, Levonyack N, Formella J, Christie A et al (2019) Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients. J Clin Oncol 37(7):S645","journal-title":"J Clin Oncol"},{"issue":"3","key":"2803_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","volume":"20","author":"M Grangeon","year":"2019","unstructured":"Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N et al (2019) Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 20(3):201\u2013207. https:\/\/doi.org\/10.1016\/j.cllc.2018.10.002","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"2803_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4(3):374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"issue":"28","key":"2803_CR28","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193\u20133198. https:\/\/doi.org\/10.1200\/JCO.2015.60.8448","journal-title":"J Clin Oncol"},{"issue":"2","key":"2803_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","volume":"145","author":"A Indini","year":"2019","unstructured":"Indini A, Guardo LD, Cimminiello C, Prisciandaro M, Randon G, Braud FD et al (2019) Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 145(2):511\u2013521. https:\/\/doi.org\/10.1007\/s00432-018-2819-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"2803_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2019.05.017","volume":"116","author":"T Kawai","year":"2019","unstructured":"Kawai T, Sato Y, Makino K, Yamada Y, Nomiya A, Nakamura M et al (2019) Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. Eur J Cancer 116:114\u2013115. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.017","journal-title":"Eur J Cancer"},{"issue":"1","key":"2803_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","volume":"19","author":"K Masuda","year":"2019","unstructured":"Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H et al (2019) Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19(1):974. https:\/\/doi.org\/10.1186\/s12885-019-6150-y","journal-title":"BMC Cancer"},{"issue":"1","key":"2803_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","volume":"41","author":"N Okada","year":"2019","unstructured":"Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y et al (2019) Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther 41(1):59\u201367. https:\/\/doi.org\/10.1016\/j.clinthera.2018.11.004","journal-title":"Clin Ther"},{"issue":"10","key":"2803_CR33","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1080\/00016489.2019.1648867","volume":"139","author":"I Okamoto","year":"2019","unstructured":"Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T et al (2019) Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study. Acta Otolaryngol 139(10):918\u2013925. https:\/\/doi.org\/10.1080\/00016489.2019.1648867","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"2803_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, Giglio AD, Bassanelli M, Giovanna MDB, Metro G et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145(2):479\u2013485. https:\/\/doi.org\/10.1007\/s00432-018-2805-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"2803_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado J, S\u00e1nchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Lev\u00ed A et al (2019) Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 109:21\u201327. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.014","journal-title":"Eur J Cancer"},{"key":"2803_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71\u201374. https:\/\/doi.org\/10.1016\/j.lungcan.2017.11.019","journal-title":"Lung Cancer"},{"issue":"3","key":"2803_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.seminoncol.2018.07.003","volume":"45","author":"H Shafqat","year":"2018","unstructured":"Shafqat H, Gourdin T, Sion A (2018) Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1\/PD-L1 therapy. Semin Oncol 45(3):156\u2013163. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.07.003","journal-title":"Semin Oncol"},{"issue":"12","key":"2803_CR38","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y et al (2017) Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12(12):1798\u20131805. https:\/\/doi.org\/10.1016\/j.jtho.2017.08.022","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2803_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","volume":"5","author":"Y Toi","year":"2019","unstructured":"Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T et al (2019) Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol 5(3):376\u2013383. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5860","journal-title":"JAMA Oncol"},{"issue":"1","key":"2803_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","volume":"7","author":"E Verzoni","year":"2019","unstructured":"Verzoni E, Carten\u00ec G, Cortes E, Giannarelli D, Giglio AD, Sabbatin R et al (2019) Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 7(1):99. https:\/\/doi.org\/10.1186\/s40425-019-0579-z","journal-title":"J Immunother Cancer"},{"key":"2803_CR41","doi-asserted-by":"crossref","unstructured":"Von Pawel J, Syrigos K, Mazieres J, Cortinovis D, Dziadziuszko R, Gandara DR, et al (2017) Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann Oncol 28(suppl 5): mdx380.017-mdx380.017","DOI":"10.1093\/annonc\/mdx380.017"},{"issue":"7","key":"2803_CR42","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/0284186X.2019.1615636","volume":"58","author":"B Bj\u00f8rnhart","year":"2019","unstructured":"Bj\u00f8rnhart B, Hansen KH, J\u00f8rgensen TL, Herrstedt J, Schytte T (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol 58(7):953\u2013961. https:\/\/doi.org\/10.1080\/0284186X.2019.1615636","journal-title":"Acta Oncol"},{"issue":"4","key":"2803_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/1346-8138.15246","volume":"47","author":"M Otsuka","year":"2020","unstructured":"Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S et al (2020) Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: a single-center retrospective study in Japan. J Dermatol 47(4):356\u2013362. https:\/\/doi.org\/10.1111\/1346-8138.15246","journal-title":"J Dermatol"},{"issue":"9","key":"2803_CR44","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2217\/imt-2016-0083","volume":"8","author":"J Dick","year":"2016","unstructured":"Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulo-strauss A et al (2016) Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 8(9):1033\u20131044. https:\/\/doi.org\/10.2217\/imt-2016-0083","journal-title":"Immunotherapy"},{"issue":"10","key":"2803_CR45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","volume":"22","author":"J Judd","year":"2017","unstructured":"Judd J, Ma Z, Handorf E, O\u2019Neill J, Ramamurthy C, Bentota S et al (2017) Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. Oncologist 22(10):1232\u20131237. https:\/\/doi.org\/10.1634\/theoncologist.2017-0133","journal-title":"Oncologist"},{"issue":"1","key":"2803_CR46","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H et al (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7(1):e1375642. https:\/\/doi.org\/10.1080\/2162402X.2017.1375642","journal-title":"Oncoimmunology"},{"issue":"1","key":"2803_CR47","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.cllc.2018.09.005","volume":"20","author":"D Ksienski","year":"2018","unstructured":"Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z et al (2018) Efficacy of nivolumab and pembrolizumab in patients with advanced nonsmall cell lung cancer needing treatment interruption due to adverse events: aretrospective multicenter analysis. Clin Lung Cancer 20(1):e97\u2013e106. https:\/\/doi.org\/10.1016\/j.cllc.2018.09.005","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"2803_CR48","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1002\/cam4.1825","volume":"7","author":"P Lesueur","year":"2018","unstructured":"Lesueur P, Escande A, Thariat J, Vaul\u00e9on E, Monnet I, Cortot A et al (2018) Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Med 7(11):5505\u20135513. https:\/\/doi.org\/10.1002\/cam4.1825","journal-title":"Cancer Med"},{"issue":"3","key":"2803_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","volume":"6","author":"A Lisberg","year":"2018","unstructured":"Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Ariana H et al (2018) Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol Res 6(3):288\u2013294. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0063","journal-title":"Cancer Immunol Res"},{"issue":"30","key":"2803_CR50","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","volume":"37","author":"VE Maher","year":"2019","unstructured":"Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M et al (2019) Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 37(30):2730\u20132737. https:\/\/doi.org\/10.1200\/JCO.19.00318","journal-title":"J Clin Oncol"},{"issue":"6","key":"2803_CR51","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","volume":"79","author":"CK Min Lee","year":"2018","unstructured":"Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY et al (2018) Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol 79(6):1047\u20131052. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.035","journal-title":"J Am Acad Dermatol"},{"issue":"47","key":"2803_CR52","doi-asserted-by":"publisher","first-page":"77404","DOI":"10.18632\/oncotarget.12677","volume":"7","author":"Y Nakamura","year":"2016","unstructured":"Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K et al (2016) Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 7(47):77404\u201377415","journal-title":"Oncotarget"},{"issue":"3","key":"2803_CR53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"issue":"6","key":"2803_CR54","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","volume":"19","author":"DH Owen","year":"2018","unstructured":"Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K et al (2018) Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer 19(6):e893\u2013e900. https:\/\/doi.org\/10.1016\/j.cllc.2018.08.008","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"2803_CR55","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151(11):1206\u20131212. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1916","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2803_CR56","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/1759-7714.13364","volume":"11","author":"T Sugano","year":"2020","unstructured":"Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N et al (2020) Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 11(4):1052\u20131060. https:\/\/doi.org\/10.1111\/1759-7714.13364","journal-title":"Thorac Cancer"},{"issue":"3","key":"2803_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00262-017-2092-x","volume":"67","author":"KJ Suh","year":"2018","unstructured":"Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM et al (2018) Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 67(3):459\u2013470. https:\/\/doi.org\/10.1007\/s00262-017-2092-x","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2803_CR58","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL et al (2017) Safety profile of nivolumab monotherapy: apooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785\u2013792. https:\/\/doi.org\/10.1200\/JCO.2015.66.1389","journal-title":"J Clin Oncol"},{"issue":"6","key":"2803_CR59","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/cas.13241","volume":"108","author":"N Yamazaki","year":"2017","unstructured":"Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujimoto M, Takenouchi T et al (2017) Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a Phase II study. Cancer Sci 108(6):1223\u20131230. https:\/\/doi.org\/10.1111\/cas.13241","journal-title":"Cancer Sci"},{"issue":"2","key":"2803_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"1","key":"2803_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.2018-0434","volume":"24","author":"PD Patil","year":"2019","unstructured":"Patil PD, Fernandez AP, Velcheti V, Tarhini A, Funchain P, Rini B et al (2019) Cases from the irAE tumor board: a multidisciplinary approach to a patient treated with immune checkpoint blockade who presented with a new rash. Oncologist 24(1):4\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2018-0434","journal-title":"Oncologist"},{"key":"2803_CR62","doi-asserted-by":"publisher","unstructured":"Le Poole IC, Wa\u00f1kowicz-Kali\u00f1ska A, van den Wijngaard RM, Nickoloff BJ, Das PK (2004) Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 9(1): 68\u201372. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/j.1087-0024.2004.00825.x","DOI":"10.1111\/j.1087-0024.2004.00825.x"},{"issue":"4","key":"2803_CR63","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","volume":"68","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A et al (2019) Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 68(4):553\u2013561. https:\/\/doi.org\/10.1007\/s00262-019-02303-1","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2803_CR64","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368\u20131379. https:\/\/doi.org\/10.1093\/annonc\/mdx108","journal-title":"Ann Oncol"},{"key":"2803_CR65","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391. https:\/\/doi.org\/10.1038\/ncomms10391","journal-title":"Nat Commun"},{"key":"2803_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","volume":"119","author":"BE Osta","year":"2017","unstructured":"Osta BE, Hu F, Sadek R, Chintalapally R, Tang SC (2017) Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"2803_CR67","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Fi Ye et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"2","key":"2803_CR68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2051","volume":"7","author":"I Melero","year":"2007","unstructured":"Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7(2):95\u2013106. https:\/\/doi.org\/10.1038\/nrc2051","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2803_CR69","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14(12):1212\u20131218. https:\/\/doi.org\/10.1038\/ni.2762","journal-title":"Nat Immunol"},{"issue":"2","key":"2803_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2020","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al (2020) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155\u2013164. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1","journal-title":"Lancet Oncol"},{"issue":"3","key":"2803_CR71","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40745","volume":"71","author":"MD Richter","year":"2019","unstructured":"Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune-checkpoint inhibitors: a single-center cohort of 61 patients. Arthritis Rheumatol 71(3):468\u2013475. https:\/\/doi.org\/10.1002\/art.40745","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2803_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"XX Zhou","year":"2020","unstructured":"Zhou XX, Yao ZR, Yang HX, Liang NX, Zhang X, Zhang FC (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 18(1):87\u2013100. https:\/\/doi.org\/10.1186\/s12916-020-01549-2","journal-title":"BMC Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02803-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02803-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T08:06:54Z","timestamp":1628755614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02803-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2803"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02803-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}